The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called homologous recombination, the cell uses loops in its ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...